Opportunities for Quantitative Translational Modeling in Oncology

Area of Science:

• Oncology
• Quantitative Systems Pharmacology (QSP)
• Translational Drug Development

Background:

• A UK Quantitative Systems Pharmacology Network meeting focused on translational challenges in oncology drug development.
• Discussions involved experts from diverse backgrounds to identify improvements in modeling applications.

Framework:

• The meeting identified four key themes for advancing quantitative pharmacology in oncology.
• Recommendations emphasize enhancing preclinical model predictivity and integrating mechanistic models across development stages.

Implementation:

• Evaluate and improve the predictivity and reproducibility of animal cancer models via precompetitive collaboration.
• Apply mechanism of action (MoA)-based mechanistic models from nonclinical data to clinical trial data.
• Utilize MoA-reflective models across datasets to quantify disease natural history and intervention responses.

Implications:

• More robust quantification of dose- and concentration-dependent adverse events using mathematical modeling and adaptive trial designs.
• Improved translation of preclinical findings to clinical efficacy and safety assessments.
• Enhanced precision in oncology drug development through advanced modeling approaches.